J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

摩根大通維持愛美醫療(FOLD.US)買入評級

moomoo資訊 · 11/08 08:32 · 評級/大行評級

J.P. Morgan analyst Anupam Rama maintains $Amicus Therapeutics (FOLD.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 46.9% and a total average return of 3.4% over the past year.

AnalystRecentRatingAutoNews_205926_20241108_02d70869fa675771437d36e0f966f9d569d0e923_1731072640717166_mm_en

Furthermore, according to the comprehensive report, the opinions of $Amicus Therapeutics (FOLD.US)$'s main analysts recently are as follows:

Amicus's third quarter revenues surpassed market expectations, recording $120.4M in Galafold sales in addition to $21.1M in purchase order sales. Following these results, adjustments were made to the quarterly model and updated guidance was factored in. Additionally, the forecast now extends to the year 2025 and the cost of goods sold has been revised upward in accordance with management's comments regarding inventory expenses for P+O.
Following a quarter where sales exceeded expectations, and the management team lifted its full-year guidance for Galafold and Pombiliti, the narrative surrounding Amicus could be very attractive to various potential acquirers in the year 2025.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根大通分析師Anupam Rama維持$愛美醫療 (FOLD.US)$買入評級。

根據TipRanks數據顯示，該分析師近一年總勝率為46.9%，總平均回報率為3.4%。

AnalystRecentRatingAutoNews_205926_20241108_02d70869fa675771437d36e0f966f9d569d0e923_1731072640717166_mm_tc

此外，綜合報道，$愛美醫療 (FOLD.US)$近期主要分析師觀點如下：

Amicus第三季度營收超過市場預期，蓋拉佛一季度銷售額爲12040萬美元，另外採購訂單銷售額爲2110萬美元。在這些結果之後，季度模型進行了調整，並考慮了更新後的指導方針。此外，預測現在延伸至2025年，根據管理層關於P+O庫存費用的評論，營業成本已經上調。
在銷售超出預期的一個季度之後，管理團隊提高了蓋拉佛和龐比利提的全年指導，並且關於Amicus的情況可能會在2025年對各種潛在收購者非常有吸引力。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating

風險及免責聲明

聲明